Sustained-Release Capsules for Colonic Microbiome Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet need for sustained-release or controlled-release formulations of polyphenols and aminosterols that can accurately and precisely deliver therapeutic agents to the colon to address neurological disorders such as Parkinson's Disease, where current therapies are inadequate, and existing formulations often result in rapid systemic absorption rather than targeted colonic delivery.
Innovation Solution
Development of sustained-release solid dosage forms comprising a core with a polyphenol or aminosterol active agent, coated with release rate controlling materials like poly(methyl methacrylate) and ethyl cellulose, designed to release the active agent slowly over a prolonged period, minimizing initial rapid release and maximizing exposure in the colon, using formulations such as mini-tablets, beads, or pellets with specific release profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If polyphenols or aminosterols are administered using conventional formulations, then systemic absorption occurs rapidly, but targeted colonic delivery is compromised
Solution Approach 1:
The dosage form is divided into multiple layers with distinct functions: an enteric coating layer that resists dissolution in acidic environments, a sustained-release matrix layer that controls drug release kinetics, and a core layer containing the active agent. This segmentation allows the formulation to survive gastric passage intact and release the drug specifically in the colon over an extended period
Solution Approach 2:
The enteric coating acts as an intermediary barrier that prevents premature dissolution and systemic absorption in the upper gastrointestinal tract. This coating layer mediates between the acidic gastric environment and the sustained-release matrix, ensuring the active agent reaches the colon before release occurs
2Manufacturing precision
If sustained-release coatings are applied to minimize rapid release, then colonic exposure is maximized, but manufacturing complexity increases
Solution Approach 1:
The formulation utilizes polymers with specific dissolution parameters (pH-dependent solubility, erosion rates, and glass transition temperatures) to achieve sustained release. By selecting polymers with appropriate parameters, the formulation achieves complex release profiles through material properties rather than mechanical complexity
Solution Approach 2:
The dosage form employs composite material structures combining hydrophobic polymers (for water resistance and sustained release), hydrophilic polymers (for controlled erosion and drug release), and enteric coatings (for pH-dependent dissolution). This composite approach achieves sophisticated release behavior through material composition rather than structural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described dosage forms achieve controlled release of the active agent, ensuring prolonged exposure in the colon, thereby effectively inhibiting amyloid aggregation and modulating colonic microbiota, providing therapeutic benefits for neurological disorders like Parkinson's Disease with improved accuracy and precision.
Implementation Method 1
a core, comprising an active agent, and optionally one or more release rate controlling material
Implementation Method 2
designed to release the active agent slowly over a prolonged period
Implementation Method 3
coated with release rate controlling materials like poly(methyl methacrylate) and ethyl cellulose, designed to release the active agent slowly
Implementation Method 4
maximizing exposure in the colon, using formulations such as mini-tablets, beads, or pellets with specific release profiles
Data Source
AI summary
Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.